Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer

Riaz, Nazia; Burugu, Samantha; Cheng, Angela; Leung, Samuel; Gao, Dongxia; Nielsen, Torsten O.

doi:10.3390/cancers13225769

Cited by 16 publications

(12 citation statements)

References 82 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CSF-1 also promotes immunosuppression through stimulating the differentiation of MDSCs and the selective activation of TAMs expressing CSF-1R and MHC-II. Immune cell infiltration with high expression of CSF-1R in the TME is usually associated with immune dysfunction and enhanced immune resistance, such as poor prognosis in ovarian cancer, breast cancer, endometrial cancer, PDAC, and lymphoma [ 129 – 132 ]. Blocking the CSF1/CSF-1R axis is the most established method for reducing the infiltration of TAMs.…”

Section: Strategies For Targeting Macrophages In the Treatment Of Sol...mentioning

confidence: 99%

Targeting macrophages: a novel treatment strategy in solid tumors

Liu

Song

et al. 2022

J Transl Med

View full text Add to dashboard Cite

In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant immune cells, which act as a key regulator in tumorigenesis and progression. Increasing evidence have demonstrated that the TME alters the nature of macrophages to maintain dynamic tissue homeostasis, allowing TAMs to acquire the ability to stimulate angiogenesis, promote tumor metastasis and recurrence, and suppress anti-tumor immune responses. Furthermore, tumors with high TAM infiltration have poor prognoses and are resistant to treatment. In the field of solid tumor, the exploration of tumor-promoting mechanisms of TAMs has attracted much attention and targeting TAMs has emerged as a promising immunotherapeutic strategy. Currently, the most common therapeutic options for targeting TAMs are as follows: the deletion of TAMs, the inhibition of TAMs recruitment, the release of phagocytosis by TAMs, and the reprogramming of macrophages to remodel their anti-tumor capacity. Promisingly, the study of chimeric antigen receptor macrophages (CAR-Ms) may provide even greater benefit for patients with solid tumors. In this review, we discuss how TAMs promote the progression of solid tumors as well as summarize emerging immunotherapeutic strategies that targeting macrophages.

show abstract

Section: Strategies For Targeting Macrophages In the Treatment Of Sol...mentioning

confidence: 99%

Targeting macrophages: a novel treatment strategy in solid tumors

Liu

Song

et al. 2022

J Transl Med

View full text Add to dashboard Cite

show abstract

“…In breast carcinoma cells, CSF-1R has been demonstrated as being functional and implicated in various biological effects, such as proliferation, invasion, and epithelial-mesenchymal transition [21,25,[49][50][51][52][53][54][55]. Moreover, its expression is correlated with poor clinical outcomes [22,56]. Thus, the role of the CSF-1/CSF-1R axis in supporting the growth and motility of several solid tumors has been well documented [57].…”

Section: Discussionmentioning

confidence: 99%

“…CSF-1R is also expressed in microglia and neural progenitor cells participating in central nervous system development [19]. CSF-1 and its receptor play a role in normal breast tissue during puberty, pregnancy, and lactation [13,20] and in breast carcinogenesis [21,22].…”

Section: Introductionmentioning

confidence: 99%

Macrophage-Colony-Stimulating Factor Receptor Enhances Prostate Cancer Cell Growth and Aggressiveness In Vitro and In Vivo and Increases Osteopontin Expression

Mougel

Adriaenssens

Guyot

et al. 2022

IJMS

View full text Add to dashboard Cite

Prostate cancer is a major public health concern and one of the most prevalent forms of cancer worldwide. The definition of altered signaling pathways implicated in this complex disease is thus essential. In this context, abnormal expression of the receptor of Macrophage Colony-Stimulating Factor-1 (M-CSF or CSF-1) has been described in prostate cancer cells. Yet, outcomes of this expression remain unknown. Using mouse and human prostate cancer cell lines, this study has investigated the functionality of the wild-type CSF-1 receptor in prostate tumor cells and identified molecular mechanisms underlying its ligand-induced activation. Here, we showed that upon CSF-1 binding, the receptor autophosphorylates and activates multiple signaling pathways in prostate tumor cells. Biological experiments demonstrated that the CSF-1R/CSF-1 axis conferred significant advantages in cell growth and cell invasion in vitro. Mouse xenograft experiments showed that CSF-1R expression promoted the aggressiveness of prostate tumor cells. In particular, we demonstrated that the ligand-activated CSF-1R increased the expression of spp1 transcript encoding for osteopontin, a key player in cancer development and metastasis. Therefore, this study highlights that the CSF-1 receptor is fully functional in a prostate cancer cell and may be a potential therapeutic target for the treatment of prostate cancer.

show abstract

“…Among them, fibroblasts were derived from primitive mesenchymal cells and had been reported to interact with cancer cells, [41,42] so they were used as normal control cells. In addition, CSF-1R overexpression had been reported around osteosarcoma, [43] breast and lung cancer tissues, [44,45] so their corresponding three cell lines were used to evaluate the biological activity of compound P1. The results of the MTT experiment were shown in Figure 3.…”

Section: In Vitro Activity Evaluationmentioning

confidence: 99%

A New 7‐Azaindole Structure Analog: Molecular Docking, Synthesis and Preliminary Biological Activity in Vitro for Anticancer

Zhan

Tong

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

In this work, a series of 7-azaindole analogs were designed by the bioisosteric principle based on the pharmacodynamic parent nucleus. Moreover,pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)pyridin-3-yl]methyl}pyrimidin-2-amine (compound P1) with the strongest interaction with colony-stimulating factor 1 receptor (CSF-1R) was screened by molecular docking. Compound P1 was successfully prepared by the six-step reaction with HPLC purity of 99.26 % and characterized by 1 H-NMR and ESI-MS spectra. In vitro bioactivity study showed that compound P1 appeared the cytotoxicity to MCF-7 and A549 cells, especially to HOS cells (IC 50 = 88.79 � 8.07 nM), while it had lower toxicity to normal L929 cells (IC 50 = 140.49 � 8.03 μM). In addition, compound P1 could induce HOS cell death by apoptosis and blocking the G0/G1 phase at nanomolar concentrations. The obtained results indicated that compound P1 might be a promising candidate compound for anticancer drug.

show abstract

Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer

Cited by 16 publications

References 82 publications

Targeting macrophages: a novel treatment strategy in solid tumors

Targeting macrophages: a novel treatment strategy in solid tumors

Macrophage-Colony-Stimulating Factor Receptor Enhances Prostate Cancer Cell Growth and Aggressiveness In Vitro and In Vivo and Increases Osteopontin Expression

A New 7‐Azaindole Structure Analog: Molecular Docking, Synthesis and Preliminary Biological Activity in Vitro for Anticancer

Contact Info

Product

Resources

About